MultiHance 相關文獻

MultiHance 優點相關文獻
 

Albiin N1. MRI of Focal Liver Lesions.Curr Med Imaging Rev. 2012 May;8(2):107-116. 

http://www.ncbi.nlm.nih.gov/pubmed/23049491

 

Pintaske J1, Martirosian P, Graf H, Erb G, Lodemann KP, Claussen CD, Schick F. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006 Mar;41(3):213-21.

www.ncbi.nlm.nih.gov/pubmed/16481903

 

Gerretsen SC1, le Maire TF, Miller S, Thurnher SA, Herborn CU, Michaely HJ, Kramer H, Vanzulli A, Vymazal J, Wasser MN, Ballarati CE, Kirchin MA, Pirovano G, Leiner T. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology. 2010 Jun;255(3):988-1000. doi: 10.1148/radiol.10090357.

www.ncbi.nlm.nih.gov/pubmed/20501735

 

Knopp MV1, Runge VM, Essig M, Hartman M, Jansen O, Kirchin MA, Moeller A, Seeberg AH, Lodemann KP. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2004 Jan;230(1):55-64.

www.ncbi.nlm.nih.gov/pubmed/14695387

 

Hu P1, Chan J, Ngo LH, Smink J, Goddu B, Kissinger KV, Goepfert L, Hauser TH, Rofsky NM, Manning WJ, Nezafat R. Contrast-enhanced whole-heart coronary MRI with bolus infusion of gadobenate dimeglumine at 1.5 T. Magn Reson Med. 2011 Feb;65(2):392-8. doi: 10.1002/mrm.22706. Epub 2010 Nov 30.

www.ncbi.nlm.nih.gov/pubmed/21264933

 

Goyen M1, Barkhausen J, Debatin JF, Kühl H, Bosk S, Testa G, Malago M, Ruehm SG. Right-lobe living related liver transplantation: evaluation of a comprehensive magnetic resonance imaging protocol for assessing potential donors. Liver Transpl. 2002 Mar;8(3):241-50.

www.ncbi.nlm.nih.gov/pubmed/11910569

 

Brismar TB1, Kartalis N, Kylander C, Albiin N. MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine. Eur Radiol. 2012 Mar;22(3):633-41. doi: 10.1007/s00330-011-2288-y. Epub 2011 Sep 28.

www.ncbi.nlm.nih.gov/pubmed/21953376

 

Manfredi R1, Maresca G, Baron RL, Cotroneo AR, De Gaetano AM, De Franco A, Pirovano G, Spinazzi A, Marano P. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging. 1999 May;9(5):704-10.

www.ncbi.nlm.nih.gov/pubmed/10331767

 

Kim JE1, Lee JM, Kim SH, Baek JH, Moon SK, Yu IS, Kim SH, Lee JY, Han JK, Choi BI. Differentiation of intraductal growing-type cholangiocarcinomas from nodular-type cholangiocarcinomas at biliary MR imaging with MR cholangiography. Radiology. 2010 Nov;257(2):364-72. doi: 10.1148/radiol.10092105. Epub 2010 Sep 9.

www.ncbi.nlm.nih.gov/pubmed/20829532

 

Algin O1, Ozlem N, Kilic E, Karaoglanoglu M, Arslan H. Gd-BOPTA-enhanced MR cholangiography findings in gall bladder perforation. Emerg Radiol. 2010 Nov;17(6):487-91. doi: 10.1007/s10140-010-0886-7. Epub 2010 Jun 29.

www.ncbi.nlm.nih.gov/pubmed/20585821

 

Martin DR1, Krishnamoorthy SK, Kalb B, Salman KN, Sharma P, Carew JD, Martin PA, Chapman AB, Ray GL, Larsen CP, Pearson TC. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging. 2010 Feb;31(2):440-6. doi: 10.1002/jmri.22024.

www.ncbi.nlm.nih.gov/pubmed/20099361

 

Seidl Z1, Vymazal J, Mechl M, Goyal M, Herman M, Colosimo C, Pasowicz M, Yeung R, Paraniak-Gieszczyk B, Yemen B, Anzalone N, Citterio A, Schneider G, Bastianello S, Ruscalleda J. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol. 2012 Jun;33(6):1050-8. doi: 10.3174/ajnr.A3033. Epub 2012 Mar 1.

www.ncbi.nlm.nih.gov/pubmed/22383237

 

Achenbach M1, Figiel JH, Burbelko M, Heverhagen JT. Prospective comparison of image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrast-enhanced run-off magnetic resonance angiography of the lower extremities. J Magn Reson Imaging. 2010 Nov;32(5):1166-71. doi: 10.1002/jmri.22355.

www.ncbi.nlm.nih.gov/pubmed/21031523

 

MultiHance 2014 相關文獻

 

Shin KS, AlObaidy M, Ramalho M, Jeon YH, Burke LM, Altun E, Stallings CG, Semelka RC. Inter- and intra-individual comparative study of two gadolinium-based agents: A pilot study.  Abdom Imaging. 2014 Sep 16

www.ncbi.nlm.nih.gov/pubmed/25223524

 

Gilbert FJ, van den Bosch HC, Petrillo A, Siegmann K, Heverhagen JT, Panizza P, Gehl HB, Pediconi F, Diekmann F, Peng WJ, Ma L, Sardanelli F, Belli P, Corcione S, Zechmann CM, Faivre-Pierret M, Martincich L. Comparison of gadobenate dimeglumine-enhanced breast MRI and gadopentetate dimeglumine-enhanced breast MRI with mammography and ultrasound for the detection of breast cancer. J Magn Reson Imaging. 2014 May;39(5):1272-86

www.ncbi.nlm.nih.gov/pubmed/25006633

 

Neizel M, Ruebben A, Weiss N, Günther RW, Kelm M, Krombach GA. Monitoring of gadolinium-BOPTA uptake into the vessel wall during magnetic resonance (MR)-guided angioplasty of the peripheral arteries with a paclitaxel/gadolinium-BOPTA-coated balloon: an experimental study at 3 Tesla. Rofo. 2014 Apr;186(4):388-93.

www.ncbi.nlm.nih.gov/pubmed/24142436

 

Yun H, Jin H, Yang S, Huang D, Chen ZW, Zeng MS. Coronary artery angiography and myocardial viability imaging: a 3.0-T contrast-enhanced magnetic resonance coronary artery angiography with Gd-BOPTA. Int J Cardiovasc Imaging. 2014 Jan;30(1):99-108.

www.ncbi.nlm.nih.gov/pubmed/24068575

 

Millet I, Curros-Doyon F, Molinari N, Bouic-Pages E, Prat X, Alili C, Taourel P. Invasive breast carcinoma: influence of prognosis and patient-related factors on kinetic MR imaging characteristics. Radiology. 2014 Jan;270(1):57-66.

www.ncbi.nlm.nih.gov/pubmed/24029641

 

MultiHance 2013 相關文獻

 

Thian YL, Riddell AM, Koh DM. Liver-specific agents for contrast-enhanced MRI: role in oncological imaging. Cancer Imaging. 2013 Dec 30;13(4):567-79.

www.ncbi.nlm.nih.gov/pubmed/24434892

 

Kinkel K, Schwenke C, Kubik-Huch R, Pediconi F. Intra-individual randomised comparison of gadobutrol 1.0 M versus gadobenate dimeglumine 0.5 M in patients scheduled for preoperative breast MRI. Eur Radiol. 2013 Aug;23(8):2097-9.

www.ncbi.nlm.nih.gov/pubmed/23712434

 

Yeom SK, Byun JH, Kim HJ, Park SH, Kim N, Shin YM, Kim PN. Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis. Magn Reson Imaging. 2013 Jul;31(6):911-7.

www.ncbi.nlm.nih.gov/pubmed/23598063

 

Ringe KI, Boll DT, Husarik DB, Bashir MR, Gupta RT, Merkle EM. Lesion detection and assessment of extrahepatic findings in abdominal MRI using hepatocyte specific contrast agents--comparison of Gd-EOB-DTPA and Gd-BOPTA. BMC Med Imaging. 2013 Mar 18;13:10. doi: 10.1186/1471-2342-13-10.

www.ncbi.nlm.nih.gov/pubmed/23506523

 

Schneider G, Schürholz H, Kirchin MA, Bücker A, Fries P. Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children. Pediatr Radiol. 2013 Jan;43(2):202-11

www.ncbi.nlm.nih.gov/pubmed/23179483

 

Kim HJ, Kim BS, Kim MJ, Kim SH, de Campos RO, Hernandes M, Semelka RC. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient. J Magn Reson Imaging. 2013 Apr;37(4):903-8.

www.ncbi.nlm.nih.gov/pubmed/23065959

 

Gatto A, De Gaetano AM, Giuga M, Ciresa M, Siciliani L, Miele L, Riccardi L, Pizzolante F, Rapaccini GL, Gasbarrini A, Giuliante F, Vecchio FM, Pompili M, Bonomo L. Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging. Abdom Imaging. 2013 Aug;38(4):736-44.

www.ncbi.nlm.nih.gov/pubmed/22986351

 

Pediconi F, Kubik-Huch R, Chilla B, Schwenke C, Kinkel K. Intra-individual randomised comparison of gadobutrol 1.0 M versus gadobenate dimeglumine 0.5 M in patients scheduled for preoperative breast MRI. Eur Radiol. 2013 Jan;23(1):84-92.

www.ncbi.nlm.nih.gov/pubmed/22797979

 

MultiHance 2012 相關文獻

 

Johansson L, Kirchin MA, Ahlström H. Gadobenate dimeglumine (MultiHance) in MR angiography: an in-vitro phantom comparison with gadopentetate dimeglumine (Magnevist) at different concentrations. Acta Radiol. 2012 Dec 1;53(10):1112-7.

www.ncbi.nlm.nih.gov/pubmed/23081961

 

Koh DM. Liver-specific contrast agents. Cancer Imaging. 2012 Sep 28;12:363-4.

www.ncbi.nlm.nih.gov/pubmed/23023233

 

Li ZL, Chen X, Xia CC, Sun JY, Li CX, Tang HH, Song B. [Comparison of the efficacy of gadobutrol and multihance in contrast-enhanced MRI for diagnosis of brain metastasis in lung cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012 Jul;43(4):601-4.

www.ncbi.nlm.nih.gov/pubmed/22997905

 

Hohmann J, Newerla C, Müller A, Reinicke C, Skrok J, Frericks BB, Albrecht T. Hepatic transit time analysis using contrast enhanced MRI with Gd-BOPTA: A prospective study comparing patients with liver metastases from colorectal cancer and healthy volunteers. J Magn Reson Imaging. 2012 Dec;36(6):1389-94.

www.ncbi.nlm.nih.gov/pubmed/22893441

 

Kawel N, Nacif M, Zavodni A, Jones J, Liu S, Sibley CT, Bluemke DA. T1 mapping of the myocardium: intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA. J Cardiovasc Magn Reson. 2012 Apr 28;14:26.

www.ncbi.nlm.nih.gov/pubmed/22540153

 

Seidl Z, Vymazal J, Mechl M, Goyal M, Herman M, Colosimo C, Pasowicz M, Yeung R, Paraniak-Gieszczyk B, Yemen B, Anzalone N, Citterio A, Schneider G, Bastianello S, Ruscalleda J. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol. 2012 Jun;33(6):1050-8.

www.ncbi.nlm.nih.gov/pubmed/22383237

 

Fu GL, Du Y, Zee CS, Yang HF, Li Y, Duan RG, Zeng NL, Xiao DM. Gadobenate dimeglumine-enhanced liver magnetic resonance imaging: value of hepatobiliary phase for the detection of focal liver lesions. J Comput Assist Tomogr. 2012 Jan-Feb;36(1):14-9.

www.ncbi.nlm.nih.gov/pubmed/22261765

 

Gupta RT, Marin D, Boll DT, Husarik DB, Davis DE, Feuerlein S, Merkle EM. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium. Eur J Radiol. 2012 Oct;81(10):2457-62.

www.ncbi.nlm.nih.gov/pubmed/22138122

 

Dahlqvist Leinhard O, Dahlström N, Kihlberg J, Sandström P, Brismar TB, Smedby O, Lundberg P. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur Radiol. 2012 Mar;22(3):642-53.

www.ncbi.nlm.nih.gov/pubmed/21984449  

 

Brismar TB, Kartalis N, Kylander C, Albiin N. MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine. Eur Radiol. 2012 Mar;22(3):633-41.

www.ncbi.nlm.nih.gov/pubmed/21953376

 

 

 

 

 

聯絡我們

普樂可醫藥股份有限公司 地址 : 台北市民生東路一段58號11樓 電話 : (02) 2521-0566
傳真 : (02) 2571-0157
p5418173@ms17.hinet.net